allogenic bone marrow transplantation in aplastic anemia

Authors

p nasseri from the bmt unit, shariati hospital, tehran university of medical sciences, tehran, islamic republic of iran.

a ghavamzadeh

m jahani

a khodabandeh

abstract

eighteen patients, twelve men and six women, with aplastic anemia underwent allogenic bone marrow transplantation (bmt) from hla-matched siblings during the period of 1990 to 1996. the conditioning regimen was cyclophosphamide with or without busulfan, depending on the cause of aplasia. antilymphocyte globulin (alg) and cyclosporine were used for rejection and acute gvhd prophylaxis, respectively. eleven patients are alive (61 %) and seven (39%) died. twelve patients developed acute gvhd. we found an inverse relationship between the incidence of acute gvhd and the number of units of transfused packed cells and platelets before bmt (p 1000, plt> 100000) after bmt was inversely related to the total number of cells transplanted (p<0.05).

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

ALLOGENIC BONE MARROW TRANSPLANTATION IN APLASTIC ANEMIA

Eighteen patients, twelve men and six women, with aplastic anemia underwent allogenic bone marrow transplantation (BMT) from HLA-matched siblings during the period of 1990 to 1996. The conditioning regimen was cyclophosphamide with or without busulfan, depending on the cause of aplasia. Antilymphocyte globulin (ALG) and cyclosporine were used for rejection and acute GVHD prophylaxis, respe...

full text

[Allogenic bone marrow transplantation].

Allogeneic bone marrow transplantation (BMT) after high-dose, marrow-ablative chemoradiotherapy has been established as the treatment of choice for various hematologic, neoplastic, and congenital disorders. The most common type of marrow graft is an allogeneic one from a sibling donor who has compatible human leukocyte antigen (HLA). Only 30% of patients requiring allogeneic BMT have an HLA-com...

full text

Allogeneic bone marrow transplantation for severe aplastic anemia.

In vitro coculture studies were performed in five patients with severe aplastic anemia (SAA) and their normal HLA-matched donors before and after allogeneic bone marrow transplantation (BMT) to determine whether the erythropoietic function of T cells is abnormal in this disorder. These coculture studies used fresh or cryopreserved marrow T lymphocytes with fresh or cryopreserved marrow T cell-d...

full text

Bone marrow transplantation for severe aplastic anemia: has outcome improved?

Bone marrow transplants for severe aplastic anemia were first performed in the 1970s. Transplant regimens, supportive care, and patient selection have changed substantially since then. Our objective was to determine the impact of these changes on transplant outcome. We studied 1,305 recipients of HLA-identical sibling transplants for aplastic anemia between 1976 and 1992, reported to the IBMTR ...

full text

5-year survival after bone marrow transplantation for aplastic anemia.

The International Bone Marrow Transplant Registry reported experience from 179 transplant teams worldwide on patients treated with bone marrow transplantation for severe aplastic anemia. The cohort consisted of 470 patients (283 male, 187 female), mean age 20 years, who received an HLA-identical sibling bone marrow transplant for aplastic anemia between 1988 and 1992. The etiology of aplastic a...

full text

Bone marrow culture in aplastic anemia.

Blood and bone marrow granulocyte colony forming units (CFUc) were assayed in 46 patients with aplastic anemia, and the serum was examined for its inhibitory action on normal CFUc growth. All patients showed a gross reduction in colonies and clusters in incidence and absolute number in the bone marrow and blood. Two proliferative abnormalities of CFUc in aplastic anaemia were identified: a sign...

full text

My Resources

Save resource for easier access later


Journal title:
medical journal of islamic republic of iran

جلد ۱۲، شماره ۳، صفحات ۲۱۷-۲۲۰

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023